biotech · Metastatic Non-Small Cell Lung Cancer · NSCLC · AVBP
ArriVent BioPharma
ArriVent BioPharma is a biotech organization headquartered in Newtown Square, USA. It trades on NYSE under ticker AVBP. Primary therapeutic focus areas include Metastatic Non-Small Cell Lung Cancer, NSCLC, Non-Small-Cell
Newtown Square, USA HQ
75 Employees
Public company Type
AVBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- Newtown Square, USA
- Employees
- 75
- Programs
- 7
- Drugs
- 4
- Patents
- 0
FURMO-002
Phase 1 · other · Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations
FURMO-002 for Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations is a Phase 1 program (other) at ArriVent BioPharma with 1 ClinicalTrials.gov record(s).
Internal code FURMO-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- ArriVent BioPharma
- Phase
- Phase 1
- Modality
- other
- Indication
- Non-Small Cell Lung Cancer (NSCLC) harboring activating EGFR or HER2 kinase domain mutations
- Status
- active
- Trials
- 1